[Market Feature] "Rare Disease AI Diagnostic Competitiveness" 3billion Rises Over 7%

The stock price of 3billion, a company providing rare genetic disease diagnostic services utilizing artificial intelligence (AI), is showing strong performance. According to an analysis report from the securities industry, "As the company demonstrates the superior performance of its proprietary AI technology and expands into the U.S. market, its earnings growth is expected to accelerate."

As of 11:39 a.m. on September 12, shares of 3billion were trading at 6,710 won, up 490 won (7.88%) from the previous trading day.

On this day, Jeong Jaewon, a researcher at iM Securities, stated, "How accurately a company can predict unknown variants is a key measure of its competitiveness," adding, "3billion's pathogenicity prediction AI has demonstrated high accuracy and effective prioritization." In fact, 3billion ranked first among the best models at the global AI genome analysis and genetic diagnostics competition organized by the U.S. National Institutes of Health.

Researcher Jeong further commented, "Considering the unique nature of rare diseases, the quality of data is more important than quantity. Currently, sales are being generated in over 70 countries, so rare disease data from multiple races, institutions, and countries are continuously accumulating." "Going forward, expansion into the U.S. market is expected to enable rapid revenue growth, as insurance coverage will be applied. The company is expected to reach profitability conservatively by 2027," he added.